English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose: To assess the impact of somatic comorbidities on stigma and the quality of life of Bulgarian patients with refractory epilepsy. Methods: We have studied 92 adult patients with refractory epilepsy, without cognitive impairment, progressive somatic, neurological disease or recent seizures. All participants fulfilled a 3-item stigma scale and QOLIE-89 questionnaire. Results: The study participants (61.96% men) had a mean disease duration 42.34 ± 1.28 years. Seventy three patients (77.17%) had focal epilepsy, 21 (22.83%) had generalized epilepsy. The etiology of the greatest percentage of participants (39.13%) was unknown, 35.87% had symptomatic epilepsy. We found stigmatization in 43.48% of the patients, 29.35% of them were severely stigmatized. There were concomitant somatic diseases in 40.22% of patients, in 16.31% - from more than one system. We proved that somatic comorbidities did not have influence on the overall score of QOLIE-89 P > 0.05 (F = 2.64) and on perceived stigma P > 0.05 (2 = 2.36). Conclusion: Somatic comorbidities in patients with refractory epilepsy do not correlate negatively with perceived stigma and does not influence the overall score of their quality of life.

SOMATIC COMORBIDITIES: HOW IMPORTANT ARE THEY FOR STIGMA AND QUALITY OF LIFE OF PATIENTS WITH REFRACTORY EPILEPSY